Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine cancer with increasing incidence.
• Risk factors include ultraviolet (UV) radiation exposure and Merkel cell polyomavirus (MCPyV) infection.

Purpose of the Study:

• To review recent advancements in MCC treatment strategies.
• To analyze the impact of viral status and immune checkpoint inhibitors (ICIs) on patient outcomes.

Main Methods:

• Literature review of current research on MCC management.
• Analysis of data on immune checkpoint inhibitors, viral status, and multimodal therapies.

Main Results:

• MCPyV-positive MCC shows significantly better median overall survival (6.6 years) than virus-negative MCC (1.2 years).
• Immune checkpoint inhibitors like avelumab and pembrolizumab have markedly improved survival rates for metastatic MCC.
• Pembrolizumab demonstrated a median OS of 24.3 months and a median PFS of 9.3 months.

Conclusions:

• Despite treatment progress, MCC recurrence rates remain substantial, underscoring the need for long-term patient monitoring.
• Future research should explore optimized combination therapies, predictive biomarkers, and refined treatment sequencing to enhance survival and quality of life.